Eliquis has a total of 2 drug patents out of which 0 drug patents have expired.
Eliquis was authorised for market use on 28 December, 2012.
Eliquis is available in tablet;oral dosage forms.
Eliquis can be used as prophylaxis of deep vein thrombosis and pulmonary embolism; reducing the risk of stroke and systemic embolism; treatment of pulmonary embolism (pe); reduce the risk of recurrent deep vein thrombosis (dvt); treatment of deep vein thrombosis (dvt); reduce the risk of recurrent pulmonary embolism; prophylaxis of deep vein thrombosis (dvt); reducing the risk of stroke; prophylaxis of pulmonary embolism.
The generics of Eliquis are possible to be released after 24 February, 2031.
Treatment: Prophylaxis of deep vein thrombosis and pulmonary embolism; Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Reduce the risk of recurrent deep vein thrombosis (...
Dosage: TABLET;ORAL
How can I launch a generic of ELIQUIS before it's drug patent expiration?
You can seek FDA approval to launch a generic drug before
the expiration of ELIQUIS's patents related
by providing a 'paragraph IV certification' in your
application, which states that the patent submitted by the
ELIQUIS's sponsor is invalid, unenforceable,
or will not be infringed by your generic product.
Here are the details of the already filed Para IV
certificates on ELIQUIS:-
Strength
Submission Date
ANDA(s) Filed
First applicant approval
Last patent expiry
180 day status
2.5 mg and 5 mg
28 Dec, 2016
25
23 Dec, 2019
24 Feb, 2031
Eligible
More Information on Dosage
Strength
Dosage
Availability
2.5MG
TABLET;ORAL
Prescription
5MG
TABLET;ORAL
Prescription
ELIQUIS family patents
900+ leading pharmaceutical companies are staying up-to-date
with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic
